Pfizer Stock: 6.4% Yield but Still Priced for Stagnation

Pfizer (PFE) shares have declined 50% from their 2021 high, resulting in a dividend yield of 6.4%, according to a report by Motley Fool. This sharp drop has made the stock look cheap, but analysts remain cautious about its future prospects.

Reasons for the Decline

The decline is primarily due to falling revenue from Pfizer's COVID-19 products (Comirnaty vaccine and Paxlovid antiviral), which were the main growth drivers during the pandemic. As demand for these products wanes, the company faces challenges in replacing that revenue with new products.

Attractive Dividend Yield

Despite the decline, Pfizer offers a dividend yield of 6.4%, one of the highest in the pharmaceutical sector. This yield may attract income-focused investors, especially in a low-interest-rate environment.

Analyst Outlook

Most analysts rate Pfizer as a Hold with an average price target of around $40, suggesting limited upside. Some analysts believe the stock may remain "dead money" in the near term until new catalysts emerge, such as new drug launches or acquisitions.

What This Means for Investors

Pfizer offers a high dividend yield but carries risks related to slowing growth. Income-seeking investors may find the stock attractive, but they should be prepared for potential price volatility. Investment decisions depend on risk tolerance and time horizon.